BioCentury | Dec 23, 2013
Company News

AstraZeneca, Bristol-Myers deal

...glucagon-like peptide-1 (GLP-1) receptor agonists Byetta exenatide and Bydureon exenatide and synthetic leptin analog Symlin...
BioCentury | Dec 23, 2013
Strategy

Diabetes take over

...drugs: the glucagon-like peptide-1 (GLP-1) receptor agonists Byetta exenatide and once-weekly Bydureon ; and Symlin pramlintide...
BioCentury | Dec 20, 2013
Top Story

Bristol-Myers selling diabetes stake to AZ

...products-- glucagon-like peptide-1 (GLP-1) receptor agonists Byetta exenatide and Bydureon exenatide and synthetic leptin analog Symlin...
BioCentury | Jan 7, 2013
Company News

Bristol-Myers, Takeda deal

...2009 deal to co-develop and commercialize obesity compounds. In 2011, the companies discontinued development of pramlintide/metreleptin...
BioCentury | Dec 27, 2012
Company News

Takeda, Amylin terminate obesity deal

...2009 deal to co-develop and commercialize obesity compounds. In 2011, the companies discontinued development of pramlintide/metreleptin...
BioCentury | Jul 9, 2012
Company News

Amylin, Bristol-Myers deal

...Bydureon exenatide, both glucagon-like peptide-1 receptor agonists; Type I and Type II diabetes drug Symlin pramlintide...
BioCentury | Jul 9, 2012
Strategy

Triple play in diabetes

...collaboration. That meant we could spend all our efforts and time evaluating Bydureon, Byetta and Symlin...
...U.S. sales force included 650 reps focused on exenatide and about 65 reps for Symlin pramlintide...
...Bydureon exenatide [Alkermes plc (NASDAQ:ALKS)] Once-weekly long-acting release (LAR) formulation of synthetic exendin-4 Mkt Symlin/SymlinPen pramlintide...
BioCentury | Jul 3, 2012
Top Story

Bristol-Myers to acquire Amylin

...Bydureon exenatide, both glucagon-like peptide-1 receptor agonists; Type I and Type II diabetes drug Symlin pramlintide...
BioCentury | Nov 14, 2011
Strategy

Betting on Bydureon

...an endocrine commercial unit of 65 representatives to market the biotech's synthetic amylin analog Symlin pramlintide...
BioCentury | Oct 3, 2011
Finance

Few Cinderellas this time

...metastatic colorectal cancer (mCRC) Amylin Pharmaceuticals Inc. (NASDAQ:AMLN)/Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) Discontinues development of pramlintide/metreleptin...
Items per page:
1 - 10 of 246